» Articles » PMID: 34636551

Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D/D Receptor Bitopic Ligands

Overview
Journal J Med Chem
Specialty Chemistry
Date 2021 Oct 12
PMID 34636551
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The crystal structure of the dopamine D receptor (DR) in complex with eticlopride inspired the design of bitopic ligands that explored (1) -alkylation of the eticlopride's pyrrolidine ring, (2) shifting of the position of the pyrrolidine nitrogen, (3) expansion of the pyrrolidine ring system, and (4) incorporation of -alkylations at the 4-position. Structure activity relationships (SAR) revealed that moving the - or expanding the pyrrolidine ring was detrimental to DR/DR binding affinities. Small pyrrolidine -alkyl groups were poorly tolerated, but the addition of a linker and secondary pharmacophore (SP) improved affinities. Moreover, -alkylated analogues showed higher binding affinities compared to analogously -alkylated compounds, e.g., -alkylated (DR, 0.436 nM and DR, 1.77 nM) vs the -alkylated (DR, 6.97 nM and DR, 25.3 nM). All lead molecules were functional DR/DR antagonists. Molecular models confirmed that 4-position modifications would be well-tolerated for future DR/DR bioconjugate tools that require long linkers and or sterically bulky groups.

Citing Articles

Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.

Conflitti P, Lyman E, Sansom M, Hildebrand P, Gutierrez-de-Teran H, Carloni P Nat Rev Drug Discov. 2025; .

PMID: 39747671 DOI: 10.1038/s41573-024-01083-3.


Linkers in Bitopic Agonists Shape Bias Profile among Transducers for the Dopamine D2 and D3 Receptors.

Semeano A, Garland R, Bonifazi A, Lee K, Famiglietti J, Zhang W ACS Pharmacol Transl Sci. 2024; 7(8):2333-2349.

PMID: 39144557 PMC: 11320723. DOI: 10.1021/acsptsci.4c00119.


Nucleus accumbens core dopamine D2 receptors are required for performance of the odor span task in male rats.

Onofrychuk T, Heidt A, Orvold S, Greba Q, Howland J Psychopharmacology (Berl). 2024; 241(5):963-974.

PMID: 38183429 DOI: 10.1007/s00213-023-06522-4.


Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D and D receptors.

Tian G, Hsieh C, Taylor M, Lee J, Riad A, Luedtke R Eur J Med Chem. 2023; 261:115751.

PMID: 37688938 PMC: 10841072. DOI: 10.1016/j.ejmech.2023.115751.


Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D (DR) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics.

Bonifazi A, Saab E, Sanchez J, Nazarova A, Zaidi S, Jahan K J Med Chem. 2023; 66(15):10304-10341.

PMID: 37467430 PMC: 11091828. DOI: 10.1021/acs.jmedchem.3c00417.


References
1.
Kumar Verma R, Abramyan A, Michino M, Free R, Sibley D, Javitch J . The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Comput Biol. 2018; 14(1):e1005948. PMC: 5786319. DOI: 10.1371/journal.pcbi.1005948. View

2.
Moritz A, Bonifazi A, Guerrero A, Kumar V, Free R, Lane J . Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D Dopamine Receptor. ACS Chem Neurosci. 2020; 11(20):3309-3320. PMC: 8262072. DOI: 10.1021/acschemneuro.0c00425. View

3.
Vangveravong S, Zhang Z, Taylor M, Bearden M, Xu J, Cui J . Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Bioorg Med Chem. 2011; 19(11):3502-11. PMC: 3118479. DOI: 10.1016/j.bmc.2011.04.021. View

4.
Beaulieu J, Gainetdinov R . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1):182-217. DOI: 10.1124/pr.110.002642. View

5.
Tan L, Zhou Q, Yan W, Sun J, Kozikowski A, Zhao S . Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. J Med Chem. 2020; 63(9):4579-4602. DOI: 10.1021/acs.jmedchem.9b01835. View